2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Inozyme Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency INZ-701 - Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 3 | Terminated | Inozyme Pharma | 2 | 2025-03-26 | 2026-09-29 |
| The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency INZ-701, Control Arm (Conventional Therapy) - Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 3 | Terminated | Inozyme Pharma | 27 | 2023-11-05 | 2026-10-01 |
Arterial calcification of infancy (2) · Hypophosphatemic Rickets, Autosomal Recessive, 1 (2)
France (2) · Saudi Arabia (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Canada (1) · Hungary (1) · Italy (1) · Spain (1) · United Arab Emirates (1) · United States (1)